عربي汉语EnglishFrançaisРусский
 
 
 
Line curve
MyGlobalFund.org
Esta información está disponible en inglés solamente

WORLD TB DAY

March 24, 2003

By Mr Tommy G. Thompson,
Chairman of the Board of the Global Fund


One third of the world’s population is infected with tuberculosis (TB).

Fifty years ago, medical science found a cure for this disease, and it seemed as if it would join polio and smallpox as a receding threat to the health and welfare of humanity. But half a century later, it is clear that the biggest challenges in beating TB lie ahead.

The illness is resurgent, abetted by new, drug-resistant strains and increasing urbanization. This year, nine million people will become sick with TB. The good news is that in most cases, TB can be cured and further spread prevented.

HIV/AIDS and TB are a lethal combination, each speeding the other’s progress. TB is the leading killer of people living with HIV/AIDS, and people infected with both are more likely to develop active TB disease. Unlike HIV, however, TB can be cured, and, through treatment, we can prevent its further spread.

The Global Fund to Fight AIDS, Malaria and Tuberculosis is at the forefront of the battle against TB.

In the next two years, the Fund will provide resources to TB programs in 16 of the 22 high-burden countries that together account for 80 percent of all cases. Over 15 percent of the resources devoted to the Fund’s first two rounds of grants will go toward fighting TB.

The Fund is committed to ensuring that programs receiving assistance use the most effective methods for detecting and treating tuberculosis.

The treatment methodology known as directly observed therapy short-course (DOTS) is the most effective means of administering treatment, curing patients, reducing transmission, and preventing the development of drug resistance.

Every TB project approved by the Global Fund in its second round of grants will incorporate DOTS, and 35 percent of them will include DOTS against multi-drug resistant strains of the disease. Over half of the Fund’s second-round TB programs include screening for HIV, and 42 percent will provide integrated treatment with HIV.

I want to dramatically increase the percentage of integrated HIV/TB projects among the total projects approved in the future. As Chair of the Board, I would like to help realize this goal by working with Board members to ensure that we are all providing the necessary technical assistance to develop more high-quality integrated proposals.

The Global Fund can and will make a profound difference in the worldwide battle against tuberculosis. The next stages of the fight will be the most challenging. It is a challenge we must meet. With the compassion of the Fund’s donors, and the passion of the Fund’s partners, we will.

Tommy G. Thompson
Chairman of the Board